In:
Journal of International Medical Research, SAGE Publications, Vol. 51, No. 1 ( 2023-01), p. 030006052211484-
Kurzfassung:
To investigate if the addition of bedaquiline and clofazimine to a treatment regimen for multidrug-resistant tuberculosis (MDR-TB) could improve patient outcomes. Methods A prospective, randomized, controlled study was conducted in patients with MDR-TB. Treatment was for 18 months. Patients in the experimental group received bedaquiline and clofazimine in addition to their regular treatment regimen whereas patients in the control group did not. Results 68 patients with MDR-TB were randomised to treatment, 34 to each group. At the end of treatment, cure rates were statistically significantly greater for the experimental group compared with the control group (82% vs. 56%). There was no difference between groups in the number of severe adverse events (3[9%]) in both groups and none were skin-related. Conclusions The addition of bedaquiline and clofazimine to the treatment regimen significantly improves outcomes for patients with MDR-TB. Clinicians should be aware of the clinical benefits of this addition but be mindful of contraindications and adverse effects.
Materialart:
Online-Ressource
ISSN:
0300-0605
,
1473-2300
DOI:
10.1177/03000605221148416
Sprache:
Englisch
Verlag:
SAGE Publications
Publikationsdatum:
2023
ZDB Id:
2082422-1
